Craft

Olainfarm

Stock Price

€9.3

2021-11-10

Market Capitalization

€130.4 M

2021-11-10

Revenue

€122.2 M

FY, 2020

Olainfarm Summary

Company Summary

Overview
Olainfarm manufactures and distributes chemical and pharmaceutical products. The company operates through five segments: medicine production, chemicals, wholesale, retail, compression materials, and others. It provides over the counter and prescription medicines, including anti-allergy, anti-inflammatory and analgesic, antibacterial, common cold, digestive system, metabolic, antifungal, and antiviral, as well as medicines for cardiovascular health, digestive and nervous systems, food supplements. Olainfarm also offers active pharmaceutical ingredients (APIs) and intermediates, pharmacovigilance services for patients and other stakeholders, as well as physicians and pharmacists, QC/QA, regulatory, APIs and intermediates development, final dosage forms development, and contract manufacturing services.
Type
Public
Status
Active
Founded
1972
HQ
Olaine, LV | view all locations
Website
https://lv.olainfarm.com/en/
Cybersecurity rating
Sectors

Key People

  • Vladimirs Krušinskis, Director of the Technical Department

    • Jeroen Weites

      Jeroen Weites, Chairman of the Board

      • Genadijs Melnis, Director of the Administrative Department

        • Vjačeslavs Krauklis, Director of the Manufacturing Department

          LocationsView all

          4 locations detected

          • Olaine HQ

            Latvia

            5 Rūpnīcu iela

          • Hlavní město Praha

            Czech Republic

            Karlovo nám. 671

          • Bratislavský kraj

            Slovakia

            Kapitulská 308/18A

          • İzmir

            Turkey

            Alsancak, Kıbrıs Şehitleri Cd. 134-1 D:204

          Olainfarm Financials

          Summary Financials

          Revenue (Q3, 2021)
          €32.4M
          Gross profit (Q3, 2021)
          €21.5M
          Net income (Q3, 2021)
          €2.3M
          Cash (Q3, 2021)
          €21.2M
          EBIT (Q3, 2021)
          €2.3M
          Enterprise value
          $117.2M

          Footer menu